Vivian Tian
Business Development
LTZ Therapeutics
I'm working on
3 years ago
Novel Myeloid Engager Platform+Assets for Oncology and Autoimmune
About
LTZ proprietary assets and platform is designed to circumvent a low prevalence of effect cells in tumor microenvironments encountered with NK engagers, and/or excessive cytokine production, a challenge often encountered with ADC/T cell engagers. Our two leading assets will be IND-ready by Q4/2024.
Partnering listings
Learn more
No Partnering listings yet
This innovator has not added partnering listings yet. For now, explore their publications, funding, and other profile details to identify promising topics to connect on.
Vivian Tian
Business Development
LTZ TherapeuticsWork experience
Business Development
Top industry applications
Not enough data yet.
Results may appear later and can be imperfect.
Results may appear later and can be imperfect.
Open to opportunities in
BiopharmaceuticsImmunotherapy
Last updated Jan 2024
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.